Skip to main
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf Inc. has demonstrated robust growth, with order entry for 2025 increasing approximately 17% year-over-year, driven by strong demand in both the banking and retail segments. The banking product revenues surged to $381 million, reflecting a 20% year-over-year increase, while total banking revenues reached $798 million, representing an 11% rise year-over-year and a notable 16% quarter-over-quarter growth. Furthermore, the company has achieved consistent positive free cash flow, with $196 million generated in the fourth quarter, indicating a solid financial foundation and a strong outlook for sustained growth into 2026 and 2027.

Bears say

Diebold Nixdorf Inc. faces a challenging outlook as the company's backlog is projected to decline sequentially, indicating potential difficulties in maintaining revenue momentum in the upcoming quarter. Additionally, operational constraints, such as tariff-related costs and supply chain disruptions, may hinder the company's ability to realize expected efficiencies and revenue growth, while a lack of consistent upgrade and replacement activity in the banking vertical raises concerns about future order trends. Despite targeting significant free cash flow generation from 2025 to 2027, the current market conditions and inherent liquidity risks suggest that the company's financial stability may remain under pressure.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.